Coronary Artery Calcium: Utilization for Primary Prevention of CHD
- 3 September 2011
- journal article
- Published by Springer Nature in Current Cardiology Reports
- Vol. 13 (6) , 465-474
Abstract
The rapidly accumulating data supporting coronary artery calcium (CAC) has necessitated multiple paradigm shifts in primary prevention: 1) CAC is the most powerful predictor of cardiac risk in the asymptomatic primary prevention population. 2) The most important role of risk factors may be to identify the modifiable targets of risk reduction in patients with risk already established by CAC. 3) “Normal cholesterol” values derived from population-based studies are not relevant for individual patients. 4) Measures of subclinical atherosclerosis (ie, serial CAC), rather than lipid values, define residual risk just as they define pretreatment risk. 5) Randomized controlled trials are not a prerequisite for implementation of CAC screening. 6) Trials evaluating lipid-treating drugs should exclude patients with 0 CAC. 7) CAC is the most cost-effective primary prevention approach.Keywords
This publication has 54 references indexed in Scilit:
- Impact of Coronary Artery Calcium Scanning on Coronary Risk Factors and Downstream TestingJACC, 2011
- Effectiveness-Based Guidelines for the Prevention of Cardiovascular Disease in Women—2011 UpdateCirculation, 2011
- Progression of Coronary Artery Calcium Predicts All-Cause MortalityJACC: Cardiovascular Imaging, 2010
- Relation Between the Framingham Risk Score, Coronary Calcium, and Incident Coronary Heart Disease Among Low-Risk MenThe American Journal of Cardiology, 2010
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinNew England Journal of Medicine, 2008
- The Editor's Roundtable: Lipid Management Beyond Statins—Reducing Residual Cardiovascular RiskThe American Journal of Cardiology, 2008
- The Deadly Double Standard (The Saga of Screening for Subclinical Atherosclerosis)The American Journal of Cardiology, 2008
- From Vulnerable Plaque to Vulnerable Patient—Part III: Executive Summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force ReportThe American Journal of Cardiology, 2006
- “Interventional lipidology”: tomographic plaque imaging and aggressive treatment of metabolic disordersThe American Journal of Cardiology, 2002
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998